Techan Inc

MX Holdings Matrix is a premier U.S.-based fuel logistics and distribution company dedicated to supporting the U.S. Government and NATO Allies in critical locations, aligning its efforts with National Security Objectives. With extensive experience in the oil and gas sector, the company provides seamless operational solutions for both public and private sector clients across Europe and the Middle East. Specializing in fuel procurement, logistics, storage, and distribution, Matrix offers a comprehensive range of services across all transportation modes, including road, maritime, air, rail, intermodal, and pipeline. The company's strategically located offices in Washington D.C., Romania, and Dubai enhance its capability to deliver effective logistics solutions worldwide. Generated from the website

Sarfez Pharmaceuticals Inc, based in Vienna, VA, is a leading pharmaceutical company specializing in the development and production of innovative medications. Their flagship product, SOAANZ torsemide tablets, is designed to effectively treat edema associated with heart failure or kidney disease with a slow drug release mechanism and minimal side effects. With a focus on patient well-being, Sarfez Pharmaceuticals offers SOAANZ at a discounted rate through various programs, making it accessible to those in need of this specialized treatment. Their commitment to quality and safety is evident in their detailed prescribing information and patient counseling, ensuring optimal outcomes for individuals using their products.Generated from the website

Perfusion Medical, LLC, based in Herndon, VA, is pioneering the development of PM-208, a novel intravenous therapeutic designed to treat hemorrhagic shock and other ischemic conditions by rapidly restoring capillary blood flow to vital organs. Backed by over $19 million in Department of Defense funding, the drug aims to improve survival outcomes significantly, as evidenced by numerous studies from leading research institutions. The primary mechanism of PM-208 involves enhancing tissue perfusion to enable oxygen delivery to oxygen-deprived tissues, countering the damaging effects of severe hypovolemic shock. As an investigational drug, PM-208 is currently undergoing development and has not yet been approved by the U.S. Food and Drug Administration. Generated from the website